Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore CNC’s full potential at InvestingPro.

HBM, STNE, CNC, and CVS stand out for low P/CF ratios and strong value scores as investors seek quality in a cautious market.

The 25% decline in Centene’s stock seems warranted given the substantial earnings adjustment and ongoing ambiguity. With more state data still forthcoming and the threat of additional earnings ...

Centene Corporation is a financially healthy company but is assessed a Hold opportunity for retail value investors due to political uncertainties about government healthcare programs and lack of a ...

Centene, a major insurer in Medicaid and ACA markets, beat Q1 estimates, raised guidance, and shows margin strength. See why CNC stock is a buy.

We are reducing our fair value estimate to $84 per share from $92 as Centene faces near-term headwinds primarily in its individual plan and Medicaid populations.

We recently changed our Uncertainty Rating for Centene to Medium from High to better reflect our assessment of the firm in the context of Morningstar’s broader coverage universe of 1,500-plus ...

S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...

--The Centene Foundation, the philanthropic arm of Centene Corporation, a healthcare enterprise focused on transforming the health of the communities it serves, today announced it has made a ...

Centene Corp (NYSE:CNC) shares are tumbling in Tuesday's after-hours session after the healthcare company withdrew its ...

Centene has agreed to sell Magellan Specialty Health to Evolent Health, the latest move in its broad value creation plan.